Clinical trials: Castrate-resistant Prostate Cancer
Immunotherapy
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
This is an experimental study to evaluate the safety and effectiveness of PSMA-targeted CAR-T cells in the treatment of castration-resistant prostate cancer.
- Trial name
- NCT05354375
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug[s]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab.
- Trial name
- NCT03972657
- Testing
- REGN5678, Cemiplimab
- Where
- 27 sites in United States, South Korea
- Volunteers
- 345 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer of the Prostate, Prostate Cancer
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
The purpose of this trial is to test if the combination of enzalutamide and metformin in patients with castration resistant prostate cancer CRPC progressing on androgen deprivation therapy ADT is more effective compared to…
- Trial name
- NCT02640534
- Testing
- Enzalutamide, Metformin
- Where
- 16 sites in Switzerland
- Volunteers
- 169 people
- Sponsor
- Swiss Cancer Institute
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Prostate Neoplasms
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
- Trial name
- NCT00473746
- Testing
- Abiraterone acetate, prednisone/prednisolone or dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Janssen Research & Development, LLC
Castration-Resistant Prostate Cancer, Prostate Cancer
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT02124668
- Testing
- Enzalutamide
- Where
- 4 sites in Georgia, Russia
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Europe B.V.
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA)…
- Trial name
- CATCH-177 (NCT06738303)
- Testing
- Cabazitaxel and carboplatin, Lu-PSMA-617
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your prostate cancer. The investigators will also watch you carefully for any side effects that PX-866 might cause.
- Trial name
- NCT01331083
- Testing
- PX-866
- Where
- 10 sites in Canada
- Volunteers
- 68 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer Castration-resistant Prostate Cancer
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
At present, no cell drug with an indication for mCRPC has been approved for marketing in China, and there is no scholar to fight against it PSMA-CAR-NK cell therapy CRPC was reported in a study.
- Trial name
- NCT07156045
- Testing
- anti-PSMA CAR-NK
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Castration-Resistant Prostate Cancer
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
- Trial name
- ENZA-p (NCT04419402)
- Testing
- Lu-PSMA, Enzalutamide
- Where
- 15 sites in Australia
- Volunteers
- 162 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Prostate Cancer
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic…
- Trial name
- AcTFirst (NCT06855277)
- Testing
- AAA817, ARPI, Standard of Care
- Where
- 106 sites in United States, Australia and 10 more
- Volunteers
- 940 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite…
- Trial name
- NCT06526299
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Washington
Prostate Cancer, Renal Cancer
64Cu-GRIP B in Patients With Advanced Malignancies
This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET)…
- Conditions
- Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor
- Trial name
- NCT05888532
- Testing
- Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Rahul Aggarwal
Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT01792687
- Testing
- ARN-509, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Docetaxel-based therapy has been shown to prolong survival as first-line therapy for patients with hormone refractory prostate cancer (HRPC), and has become the standard of care.
- Trial name
- NCT00216099
- Testing
- Pemetrexed, Folic Acid, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Christopher Sweeney, MBBS
Hormone Refractory Prostate Cancer
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Docetaxel and sunitinib will be compared to docetaxel for their effect on CEC/CEP spikes induced by docetaxel in HRPC patients
- Trial name
- NCT00795171
- Testing
- Docetaxel * Sunitinib, Docetaxel
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate…
- Trial name
- NCT06615752
- Testing
- green tea and quercetin + docetaxel
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Charles Drew University of Medicine and Science
Hormone Refractory Prostate Cancer, Bone Metastases
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
- Trial name
- NCT00156884
- Testing
- strontium-89, cisplatin
- Where
- 2 sites in Canada
- Volunteers
- 58 people
- Sponsor
- Alberta Health services
Prostate Cancer
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic…
- Trial name
- NCT00003626
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate, Carcinoma
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
The purpose of this study was to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia in hormone-refractory (not responding to hormone…
- Trial name
- NCT00364455
- Testing
- Epoetin alfa
- Volunteers
- 56 people
- Sponsor
- Janssen-Ortho Inc., Canada
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.